Experimental antibody takes aim at Hard-to-Treat lymphoma
NCT ID NCT07332507
First seen Jun 25, 2026 · Last updated Aug 12, 2026 · Updated 10 times
Summary
This early-phase trial tests a drug called teclistamab in 30 adults with plasmablastic lymphoma that has returned or not responded to prior treatment. Teclistamab is a bispecific antibody designed to attach to both cancer cells and immune T-cells, helping the immune system attack the cancer. The study will check for side effects, find the best dose, and see if the drug can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Teclistamab (a bispecific antibody that binds to BCMA on cancer cells and CD3 on immune T-cells)
- What this could lead to
- If this trial succeeds, teclistamab could offer a new treatment option for patients with plasmablastic lymphoma that has returned or not responded to standard therapy.
- What could go wrong
- This is an early Phase 1b trial with only 30 participants, so results are preliminary. The drug may cause side effects or fail to shrink tumors in many patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PLASMABLASTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Comprehensive Cancer Center
RECRUITINGDuarte, California, 91010, United States
Contact Email: •••••@•••••
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.